Project no. POIR.01.01.01-00-0235/20

Pikralida sp. z o. o. and Nencki Institute of Experimental Biology conduct the project co-financed from the European Funds named Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.

Project no. POIR.01.01.01-00-0235/20 is implemented under the Smart Growth Operational Program 2014 – 2020, Priority Axis I “Support for R&D activites of enterprises”, subaction 1.1.1. Industrial research and developmental activities conducted by enterprises.

The aim of the project is to develop a breakthrough therapeutic solution protecting against the development of post-traumatic and post-stroke epilepsy based on the inhibition of the epileptogenesis process through the activity modulation of the enzymatic protein, matrix metalloprotease 9 (MMP-9). The project covers, among others, the development of the manufacturing technology for the active substance and investigational medicinal product, therapeutic potential analysis for the MMP-9 inhibitor in animal models, and conduction of the pre-clinical and phase I clinical studies.

• Project budget: 21,564,812.50 PLN
• Co-financing of the project from the European Funds: 16,919,633.00 PLN
• Project timeline: 01.01.2021 – 31.12.2023

The project is co-financed by the European Union under the Smart Growth Operational Program. The program is implemented as part of 3/1.1.1/2020 Fast track for Mazovia competition organized by the National Center for Research and Development.

Co-funded projects: